- Home
- CUE vs PDSB Comparison
CUE vs PDSB Comparison
Compare CUE & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- PDSB
- Stock Information
- Founded
- CUE 2014
- PDSB 2005
- Country
- CUE United States
- PDSB United States
- Employees
- CUE N/A
- PDSB N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- PDSB Health Care
- Exchange
- CUE Nasdaq
- PDSB Nasdaq
- Market Cap
- CUE 58.9M
- PDSB 43.1M
- IPO Year
- CUE 2018
- PDSB N/A
- Fundamental
- Price
- CUE $0.77
- PDSB $1.22
- Analyst Decision
- CUE Strong Buy
- PDSB Strong Buy
- Analyst Count
- CUE 3
- PDSB 3
- Target Price
- CUE $3.00
- PDSB $10.00
- AVG Volume (30 Days)
- CUE 159.5K
- PDSB 209.8K
- Earning Date
- CUE 05-20-2025
- PDSB 05-14-2025
- Dividend Yield
- CUE N/A
- PDSB N/A
- EPS Growth
- CUE N/A
- PDSB N/A
- EPS
- CUE N/A
- PDSB N/A
- Revenue
- CUE $9,287,000.00
- PDSB N/A
- Revenue This Year
- CUE N/A
- PDSB N/A
- Revenue Next Year
- CUE $25.99
- PDSB N/A
- P/E Ratio
- CUE N/A
- PDSB N/A
- Revenue Growth
- CUE 69.16
- PDSB N/A
- 52 Week Low
- CUE $0.45
- PDSB $0.85
- 52 Week High
- CUE $2.26
- PDSB $4.42
- Technical
- Relative Strength Index (RSI)
- CUE 44.09
- PDSB 50.21
- Support Level
- CUE $0.71
- PDSB $1.20
- Resistance Level
- CUE $0.78
- PDSB $1.40
- Average True Range (ATR)
- CUE 0.06
- PDSB 0.10
- MACD
- CUE 0.01
- PDSB 0.00
- Stochastic Oscillator
- CUE 38.26
- PDSB 46.92
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.